Mini Symposium on Endometrial Cancer

Title: Endometrial cancer - How will new molecular knowledge influence the way we are treating our patients?

Date: Wednesday Oct 21 2020, at 15-17

Place: Digital event in Zoom, as webinar.
To log on: https://uib.zoom.us/j/64685319557?pwd=S0pETTQ2QTU3b0JGQU1TbTRIaUE4UT09
Passcode: 4M^akV@Y

The incidence of endometrial cancer is rising both due to increased life-expectancy and higher degree of obesity in the population. Traditionally, endometrial cancer has been histologically classified and risk stratified based on clinico-pathological parameters. Molecular classification has the potential to replace histology for risk classification if solid molecular markers can be identified. The Cancer Genome Atlas (TCGA) endometrial cancer project described four distinct prognostic EC subtypes based on genomic abnormalities that reflect EC tumor biology: ultramutated, hypermutated, copy-number low and copy-number high subtypes. Subsequently, molecular and histopathologic classifiers have been suggested and evaluated for their prognostic and predictive value. The impact of molecular classification is evident and opens for development and use of more targeted therapies, and will be recognized by the upcoming WHO classification. This minisymposium will focus on the current status for risk-stratification of endometrial cancer, and highlight the need for implementation of current knowledge in the clinic to improve treatment for endometrial cancer patients.

Speakers:

Alicia Leon del Castillo, Leiden: "Histologic subtyping and grading, or Molecular classification? Endometrial cancer diagnosis in 2020.»

Alexandra Leary, Paris: "Endometrial cancer in the era of targeted therapy"

Mansoor R Mirza, Copenhagen: "The new ESGO guidelines for treatment of endometrial cancer"

Katrine Woie, Bergen / Ane Gerda Zahl Eriksson, Oslo: "The new Norwegian guidelines for treatment of endometrial cancer"

Chairs: Camilla Krakstad and Line Bjørge